Secondary childhood acute myeloid leukemia with complex karyotypic anomalies including monosomy 7, monosomy 5 and translocation (1;10) after 131I- metaiodobenzylguanidine therapy for relapsed neuroblastoma
Turkish Journal of Pediatrics, cilt.53, sa.1, ss.83-86, 2011 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 53 Sayı: 1
- Basım Tarihi: 2011
- Dergi Adı: Turkish Journal of Pediatrics
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.83-86
- Anahtar Kelimeler: 131I-metaiodobenzylguanidine, Monosomy 5 and 7, Neuroblastoma, Secondarymyeloid leukemia, Translocation (1;10)
- Ankara Üniversitesi Adresli: Evet
Özet
The prognosis for relapsing or refractory neuroblastoma (NB) remains dismal, with a five-year disease-free survival of <20%, and no effective salvage treatment has been identified so far. 131I-metaiodobenzylguanidine (131I-MIBG) has come to play an essential role in the imaging and therapy of NB over the past 30 years. The role of 131I-MIBG in the treatment of NB is continually expanding. 131I-MIBG treatment together with cumulative doses of other alkylating agents has potential serious late side effects such as myelodysplasia and leukemia, although rare. We describe a secondary acute myeloid leukemia case with complex karyotypic anomalies that included monosomy 5, monosomy 7 and translocation (1;10) in a child with relapsed NB who received therapeutic 131I-MIBG.